New Leaf Venture Partners
is a leading healthcare technology focused venture capital firm with a
team of senior partners that has been successfully investing together
for nearly 2 decades. The New Leaf team has invested over $1.7 billion
in 129 healthcare technology companies within 6 distinct funds since
1995. NLV focuses on investments in the biopharmaceutical,
information convergence (HCIT), medical device,
and biological research tools & infrastructure sectors.
Our goal is to generate outstanding returns for our limited partners by
building strong companies that are developing clinically important and
commercially attractive products.
Across all sectors and stages, the New Leaf team is focused on building
value in companies by creating strong management teams and then
collaborating with them to develop, manage, and execute capital
efficient business plans. Investment decisions are primarily driven by a
fundamental assessment of the risks in the underlying development
programs (i.e., technical, clinical, regulatory, financial, and
commercial risks). Through these efforts, New Leaf has earned a
reputation as a value-added investor and has created consistently
top-performing portfolios of healthcare technology investments.
The NLV investment team has deep operating experience and medical and
technical expertise as well as broad networks of noteworthy advisors and
consultants across academia, industry, and clinical medicine which are
integral to our active investment approach. This allows us to work
closely with founders, management, and co-investors on identifying and
achieving optimal paths to value creation and exit.
NLV Partners has offices in New York and San Mateo, California. We are
currently investing through our various funds.
Edge Therapeutics Completes Enrollment in Phase 1/2 NEWTON Study of EG-1962 for Patients with Ruptured Brain Aneurysm
Kit Check Tracks Five Million Hospital Medications with RFID and Cloud Software Solution
Meet the 2015 CNBC Disruptor 50 companies (Intarcia)
Dimension Therapeutics Secures $65 Million in Oversubscribed Series B Financing
Versartis Initiates Phase 2/3 Trial of VRS-317 in Japan for Children With Growth Hormone Deficiency